EMJ Podcast: Insights For Healthcare Professionals

This two-part podcast series delves into vitiligo as a systemic disease, its known risk factors, and the stigma often associated with the condition.   Featuring experts Amit G. Pandya, University of Texas Southwestern Medical Centre, Dallas, USA, and Thierry Passeron, Université Côte d’Azur, Nice, France, this podcast series also discusses the goals to consider in the management of patients with vitiligo, and the levels of patient satisfaction associated with current treatment options.   This podcast was funded by AbbVie. The content of the podcast reflects the opinions of the speakers and does not necessarily reflect the views of AbbVie.   Additional insights on living with vitiligo are available in an informative infographic, ‘The Unmet Need for Patients with Vitiligo is High’, which gives an overview of the condition’s symptoms and their impact, whilst also highlighting the comorbidities and management gaps that patients with vitiligo may experience.

This two-part podcast series delves into vitiligo as a systemic disease, its known risk factors, and the stigma often associated with the condition.   Featuring experts Amit G. Pandya, University of Texas Southwestern Medical Centre, Dallas, USA, and Thierry Passeron, Université Côte d’Azur, Nice, France, this podcast series also discusses the goals to consider in the management of patients with vitiligo, and the levels of patient satisfaction associated with current treatment options.   This podcast was funded by AbbVie. The content of the podcast reflects the opinions of the speakers and does not necessarily reflect the views of AbbVie.   Additional insights on living with vitiligo are available in an informative infographic, ‘The Unmet Need for Patients with Vitiligo is High’, which gives an overview of the condition’s symptoms and their impact, whilst also highlighting the comorbidities and management gaps that patients with vitiligo may experience.

This week, Jonathan is joined once more by Neil Patel, Neonatologist and Clinical Innovation Director at the Royal Hospital for Children in Glasgow, UK, to explore innovations in neonatology. In this episode, Patel discusses his work in revolutionising neonatal care by embracing the use of video messaging in order to promote family involvement, and Patel’s vision to open a centre for innovation at the Royal Hospital.

Use the following timestamps to navigate the topics discussed in this episode:

(00:00)-Introduction 

(00:34)-vCreate and the challenges of introducing medical innovations 

(09:30)-Opening a Centre for Innovation in Glasgow 

(13:27)-Challenges in maternal and neonatal care 

(17:03)-Three wishes for the future of healthcare 

In this final episode, the experts consider the patient perspective of managing type 2 diabetes and its complications while tailoring treatment approaches to individual characteristics. They also consider the patient's needs with a focus towards incretin/gut hormones and providing practical insights for healthcare practice.

 

This podcast is provided by EMJ and was supported by independent funding from Eli Lilly and Company, who did not influence the content of it. This educational activity is intended for an audience of non-US healthcare professionals.

 

Prof Michael Nauck

Head of Clinical Research at the Diabetes Division Medical Department of St. Josef-Hospital, Ruhr-University in Bochum, Germany.

Professor Nauck’s research interests include the pivotal role of gastrointestinal peptide hormones, including incretins, in both the physiological and therapeutic regulation of metabolism, as well as in the pathophysiology of type 2 diabetes. His groundbreaking contributions have been significant in shaping the treatment landscape of type 2 diabetes. He has played a pivotal role in developing novel therapeutic agents based on anti-diabetic properties of the gut hormone including GLP-1 (or Glucagon-like peptide-1).

His extensive scholarly output is underscored by numerous publications, and his outstanding scientific contributions have been honoured with several awards and accolades, including the Paul Langerhans Medal (2012) bestowed by the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes in 2022.

 

Dr. Priya Manjoo

Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia in Canada. 

Dr Manjoo is a diplomat of the American Board of Obesity Medicine and a Certified Specialist in Hypertension Medicine. She is also the director of the CardioMetabolic Collaborative Clinic located in Victoria, British Columbia, Canada and a member of the Victoria Lipid Clinic. She is a co-author of the Pharmacotherapy Section of the 2020 Canadian Adult Obesity Clinical Practice guidelines, as well as the 2022 chapter update and is an author of the 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia in Adults. Dr. Manjoo is a key opinion leader in the realms of diabetes, dyslipidaemia, and obesity management. Her invaluable contributions significantly contribute to advancing our understanding of these critical medical concepts.

This week, Jonathan is joined by Neil Patel, Neonatologist and Clinical Innovation Director at the Royal Hospital for Children in Glasgow, UK, to explore innovations in neonatology. Patel discusses his work on diaphragmatic hernia, a condition that requires multidisciplinary input and lifelong care. He further explains his role with the Scottish Women’s and Children’s Health Innovation Consortium, and the potential of the mOm Incubator for thermal regulation in newborns.

(00.00)-Introduction

(02.43)-Heart function through the medium of dance

(04.20)-Neil's route into paediatric medicine

(08.05)-Diaphragmatic hernia

(12.21)-Interests in innovation

(17.55)-mOm Incubators

(21.49)-Crossing the valley of doom

Antoni Chan, Consultant Rheumatologist and Associate Medical Director at the Royal Berkshire NHS Foundation Trust, Reading, UK, and Jonathan discuss digital healthcare technology and remote monitoring, and how they have impacted the field of rheumatology. Chan provides further detail, exploring how virtual multidisciplinary teams are used in the field, and touches on the digital tools and wearables that can be used to track patients with chronic conditions.

 

Use the following timestamps to navigate the content in this episode:

(00:00)-Introduction

(02:10)-What first led Antoni into medicine

(03:14)-Antoni’s specific interests in rheumatology and ankylosing spondylitis

(05:51)-Antoni’s doctoral thesis

(07:20)-Referrals and collaboration in primary care

(09:04)-The impacts of digital healthcare technology in rheumatology

(12:11)-Specific digital tools and wearables showing promise in the management of chronic conditions

(14:05)-Using technology to improve collaboration with healthcare professionals, and communication with patients

(16:12)-The future of digital healthcare in rheumatology: trends and anticipations

(17:23)-Artificial intelligence and machine learning algorithms

(18:27)-Three wishes for the future of healthcare

In this episode, the experts focus on incretin hormones, their clinical benefits, and therapeutic approaches, providing valuable insights into incretin-based therapies, and the perspectives of the EASD-ADA guidelines and when it is clinically appropriate to start prescribing incretins for blood glucose control.

This podcast is provided by EMJ and was supported by independent funding from Eli Lilly and Company, who did not influence the content of it. This educational activity is intended for an audience of non-US healthcare professionals.

 

Prof Michael Nauck

Head of Clinical Research at the Diabetes Division Medical Department of St. Josef-Hospital, Ruhr-University in Bochum, Germany.

Professor Nauck’s research interests include the pivotal role of gastrointestinal peptide hormones, including incretins, in both the physiological and therapeutic regulation of metabolism, as well as in the pathophysiology of type 2 diabetes. His groundbreaking contributions have been significant in shaping the treatment landscape of type 2 diabetes. He has played a pivotal role in developing novel therapeutic agents based on anti-diabetic properties of the gut hormone including GLP-1 (or Glucagon-like peptide-1).

His extensive scholarly output is underscored by numerous publications, and his outstanding scientific contributions have been honoured with several awards and accolades, including the Paul Langerhans Medal (2012) bestowed by the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes in 2022.

 

Dr. Priya Manjoo

Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia in Canada. 

Dr Manjoo is a diplomat of the American Board of Obesity Medicine and a Certified Specialist in Hypertension Medicine. She is also the director of the CardioMetabolic Collaborative Clinic located in Victoria, British Columbia, Canada and a member of the Victoria Lipid Clinic. She is a co-author of the Pharmacotherapy Section of the 2020 Canadian Adult Obesity Clinical Practice guidelines, as well as the 2022 chapter update and is an author of the 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia in Adults. Dr. Manjoo is a key opinion leader in the realms of diabetes, dyslipidaemia, and obesity management. Her invaluable contributions significantly contribute to advancing our understanding of these critical medical concepts.

Join Jonathan as he welcomes back Greg Marcus, Endowed Professor of Atrial Fibrillation, and Professor of Residence (Medicine) at the University of California, San Francisco, USA. They discuss how ethnicities need to be researched with regard to atrial fibrillation, including how adverse outcomes differ depending on an individual’s ethnicity. They also talk about digital health, and how AI devices encourage people to become more aware of their own health.

 

Use the following timestamps to navigate the content in this episode:

(00:00)-Introduction

(00:37)-The economics of cardiac disease prevention and cardiac devices

(05:00)-Genetic risk across ethnic groups

(07:54)-Atrial fibrillation detected by smart watches

(12:05)-AI in cardiology

(12:49)-A new energy for common catheter ablation

(15:14)-Personalised medicine

(16:53)-Advice for young cardiologists

(20:59)-Three wishes for the future of healthcare

The publication of this podcast was funded by QIAGEN.

Tune in to our latest podcast for valuable insights on non-small cell lung cancer (NSCLC). Esteemed contributors to this discussion include Terri Conneran, a Patient Advocate and founder of KRAS Kickers, and Colin Lindsay, a Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie in Manchester, UK. Both experts underscore the pivotal importance of biomarkers, diagnostic technologies, and collaborative efforts in enhancing survivorship.

During this episode, you'll hear about the need for early biomarker testing in NSCLC, along with a forward-looking exploration of the field's future. Lindsay offers an overview of the current treatment landscape for NSCLC, shedding light on issues like late diagnosis and targeted therapies, as well as outlining next-generation sequencing and liquid biopsy as tools to enhance NSCLC testing. Patient experiences are explored, with Conneran sharing her personal journey with diagnosis and treatment.

Speaker Bios:

Terri Conneran – Patient Advocate and Founder of KRAS Kickers, Charlotte, North Carolina. United States.

Colin Lindsay - Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie, Manchester

In this episode, the experts dive deeper into the mechanisms and physiological targets through which incretin hormones work (GLP-1), ensuring the harmonious balance of glucose metabolism and appetite regulation. They explore the intricate molecular pathways and unveil the physiological effects that arise from the actions of these messengers.

This podcast is provided by EMJ and was supported by independent funding from Eli Lilly and Company, who did not influence the content of it. This educational activity is intended for an audience of non-US healthcare professionals.

Prof Michael Nauck

Head of Clinical Research at the Diabetes Division Medical Department of St. Josef-Hospital, Ruhr-University in Bochum, Germany.

Professor Nauck’s research interests include the pivotal role of gastrointestinal peptide hormones, including incretins, in both the physiological and therapeutic regulation of metabolism, as well as in the pathophysiology of type 2 diabetes. His groundbreaking contributions have been significant in shaping the treatment landscape of type 2 diabetes. He has played a pivotal role in developing novel therapeutic agents based on anti-diabetic properties of the gut hormone including GLP-1 (or Glucagon-like peptide-1).

His extensive scholarly output is underscored by numerous publications, and his outstanding scientific contributions have been honoured with several awards and accolades, including the Paul Langerhans Medal (2012) bestowed by the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes in 2022.

Dr. Priya Manjoo

Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia in Canada.  

Dr Manjoo is a diplomat of the American Board of Obesity Medicine and a Certified Specialist in Hypertension Medicine. She is also the director of the CardioMetabolic Collaborative Clinic located in Victoria, British Columbia, Canada and a member of the Victoria Lipid Clinic. She is a co-author of the Pharmacotherapy Section of the 2020 Canadian Adult Obesity Clinical Practice guidelines, as well as the 2022 chapter update and is an author of the 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia in Adults. Dr. Manjoo is a key opinion leader in the realms of diabetes, dyslipidaemia, and obesity management. Her invaluable contributions significantly contribute to advancing our understanding of these critical medical concepts.